Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104507 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of APD356 in the Treatment of Obesity
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
NCT00104507 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 400 participants.
The verdict
NCT00104507, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
Study Summary
This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c receptor agonist, in clinical development as a potential treatment for obesity. The purpose of this study is to obtain preliminary assessment of the safety and efficacy of APD356, when administered daily for 28 days, in obese subjects who are otherwise healthy.
Interventions
- DRUG APD356
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2004-12 |
| Est. Completion | 2005-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00104507
The ClinicalTrials.gov registry entry for NCT00104507 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which APD356 is the first listed.
NCT00104507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00104507 about?
NCT00104507 is a clinical study titled "Safety and Efficacy of APD356 in the Treatment of Obesity". This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c receptor agonist, in clinical development as a potential treatment for obesity. The purpose of this study is to obtain preliminary assessment of the safety and efficacy of APD356, when administered daily for 28 d...
What is the current status of trial NCT00104507?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2004-12. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00104507?
The interventions under investigation include: APD356 (DRUG).
Who is sponsoring clinical trial NCT00104507?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.